We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Following a report of a chromosomal abnormality in a patient, the FDA has placed a hold on Allogene Therapeutics’ early-stage chimeric antigen receptor T (CAR-T) therapy clinical trials. Read More
An unspecified safety signal has slammed the brakes on Takeda Pharmaceutical’s twin studies of TAK-994, an investigational oral orexin agonist intended for the treatment of excessive daytime sleepiness in patients with narcolepsy type 1 (NT1), a chronic neurological disorder that alters the sleep-wake cycle. Read More
Although efficacy of the Pfizer vaccine against nonDelta COVID-19 infection dropped from 97 percent to 67 percent after five months, its protection against COVID-19 hospital admission — including admissions with Delta variant illness — remained high, according to a large database study published this week in The Lancet. Read More
Johnson and Johnson’s investigational vaccine against respiratory syncytial virus (RSV) reduced the risk of RSV-associated lower respiratory tract disease by 80 percent in older adults in a phase 2b trial. Read More
In addition to an 87 percent drop in risk of hospitalization and death by day 28, the results also showed an 81 percent reduction in risk of medical visits due to COVID-19 compared with placebo. Read More